Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ajanta PharmaNSE:AJANTPHARM -0.66%95 Days Payable is 151.49 as of Jun. 2026, which is 3% above its 10-year median of 147.30. GuruFocus rates NSE:AJANTPHARM with a GF Score™ of 95/100 and a GF Value™ of ₹3,348.50 (Fairly Valued). The stock has 6 warning signs investors should review. Among 925 Drug Manufacturers companies, Ajanta Pharma ranks better than 73.3% on this metric.
The historical rank and industry rank for Ajanta Pharma's Days Payable or its related term are showing as below:
NSE:AJANTPHARM'
s Days Payable Range Over the Past 10 Years
Min: 122.56 Med: 147.3 Max: 204.61
Current: 140.65
During the past 13 years, Ajanta Pharma's highest Days Payable was 204.61. The lowest was 122.56. And the median was 147.30.
NSE:AJANTPHARM's Days Payable is ranked better than 73.3% of 925
companies
in the Drug Manufacturers industry
Industry Median: 89.7
vs NSE:AJANTPHARM: 140.65
Ajanta Pharma's Days Payable
increased
from Jun. 2025 (150.23) to Jun. 2026 (151.49).
It may suggest that Ajanta Pharmadelayed paying its suppliers.
The historical data trend for Ajanta Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ajanta Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ajanta Pharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ajanta Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Ajanta Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ajanta Pharma's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ajanta Pharma (NSE:AJANTPHARM) has a Days Payable of 151.49 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ajanta Pharma and its competitors. This is near median its historical median of 147.30. Over the past decade, Ajanta Pharma's Days Payable has ranged from 122.56 to 204.61. According to the industry distribution chart, Ajanta Pharma ranks #247 out of 925 companies in the Drug Manufacturers industry, placing it in the top 26.7%.
Is Ajanta Pharma's Days Payable too high?
Ajanta Pharma's current Days Payable of 151.49 is near median its 10-year median of 147.30. Over the past 10 years, this metric has ranged from a low of 122.56 to a high of 204.61. The Drug Manufacturers industry median Days Payable is 89.70. Ajanta Pharma's value of 151.49 is 68.9% above this industry median. Based on the distribution chart, Ajanta Pharma ranks #247 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ajanta Pharma has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ajanta Pharma's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ajanta Pharma ranks #247 out of 925 companies for Days Payable. This puts Ajanta Pharma in the upper half of its industry. The industry median Days Payable is 89.70. Ajanta Pharma's value of 151.49 is 68.9% above this benchmark. Historically, Ajanta Pharma's own Days Payable has ranged from 122.56 to 204.61 over the past decade. While the company's 10-year median is 147.30 vs. the industry median of 89.70, Ajanta Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.70, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ajanta Pharma's current Days Payable of 151.49 is 68.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ajanta Pharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ajanta Pharma's current Days Payable is 151.49, which is near median its own 10-year median of 147.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ajanta Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ajanta Pharma (NSE:AJANTPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹3,348.50, compared to a current price of ₹3,481.70 — trading 4% above its estimated fair value. The current Days Payable is 151.49, which is near median its 10-year median of 147.30 and 68.9% above the Drug Manufacturers industry median of 89.70. Ajanta Pharma's overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ajanta Pharma (NSE:AJANTPHARM), the current Days Payable is 151.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ajanta Pharma (NSE:AJANTPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Ajanta Pharma stock appears to be overvalued.
The current stock price of ₹3,481.70 is trading 4% above its estimated GF Value™ of ₹3,348.50.
GuruFocus considers Ajanta Pharma to be Fairly Valued.
Key valuation signals for NSE:AJANTPHARM:
Days Payable: 151.49 (near median its 10-year median of 147.30)
GF Value™: ₹3,348.50 vs. price of ₹3,481.70 (4% above fair value)
Industry Position: 68.9% above the Drug Manufacturers median (#247 of 925)
No single metric tells the full story. See the NSE:AJANTPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ajanta Pharma Ltd is mainly involved in development, manufacturing and marketing of speciality pharmaceutical finished dosages. The operations of the Group are limited to only one segment viz. pharmaceuticals and related products. The company has presence in India, Emerging Market, Africa Institution, and USA. The company generates majority of revenue from Emerging market.
95GF Score
Get the complete analysis for NSE:AJANTPHARM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AJANTPHARM has been successfully added to your 
